Atara Biotherapeutics (ATRA)
(Delayed Data from NSDQ)
$7.79 USD
-0.14 (-1.77%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $7.82 +0.03 (0.39%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth A Momentum B VGM
Atara Biotherapeutics (ATRA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$12.75 | $18.00 | $9.00 | 60.78% |
Price Target
Based on short-term price targets offered by four analysts, the average price target for Atara Biotherapeutics comes to $12.75. The forecasts range from a low of $9.00 to a high of $18.00. The average price target represents an increase of 60.78% from the last closing price of $7.93.
Analyst Price Targets (4 )
Broker Rating
Atara Biotherapeutics currently has an average brokerage recommendation (ABR) of 2.43 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 2.43 a month ago based on seven recommendations.
Of the seven recommendations deriving the current ABR, three are Strong Buy, representing 42.86% of all recommendations. A month ago, Strong Buy represented 42.86%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 2 | 2 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 3 | 3 | 3 | 4 | 4 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 1 | 1 | 2 |
ABR | 2.43 | 2.43 | 2.43 | 2.71 | 3.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
9/5/2024 | Evercore Partners | Jonathan Miller | Hold | Hold |
8/21/2024 | H.C. Wainwright & Co. | Robert Burns | Hold | Hold |
8/16/2024 | Mizuho SecuritiesUSA | Salim Syed | Hold | Strong Buy |
8/13/2024 | Not Identified | Not Identified | Hold | Hold |
8/13/2024 | Canaccord Genuity | John L Newman | Strong Buy | Strong Buy |
7/17/2024 | Goldman Sachs | Salveen Richter | Strong Sell | Strong Sell |
4/1/2024 | Cowen & Co. | Philip M Nadeau | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.43 |
ABR (Last week) | 2.43 |
# of Recs in ABR | 7 |
Average Target Price | $12.75 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 85 of 253 |
Current Quarter EPS Est: | -3.77 |
ATRA FAQs
Atara Biotherapeutics, Inc. (ATRA) currently has an average brokerage recommendation (ABR) of 2.43 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 7 brokerage firms.
The average price target for Atara Biotherapeutics, Inc. (ATRA) is $12.75. The current on short-term price targets is based on 3 reports.
The forecasts for Atara Biotherapeutics, Inc. (ATRA) range from a low of $9 to a high of $18. The average price target represents a increase of $60.78 from the last closing price of $7.93.
The current UPSIDE for Atara Biotherapeutics, Inc. (ATRA) is 60.78%
Based on short-term price targets offered by four analysts, the average price target for Atara Biotherapeutics comes to $12.75. The forecasts range from a low of $9.00 to a high of $18.00. The average price target represents an increase of 60.78% from the last closing price of $7.93.